Synthesis of Chitosan Oligosaccharide-Loaded Glycyrrhetinic Acid Functionalized Mesoporous Silica Nanoparticles and In Vitro Verification of the Treatment of APAP-Induced Liver Injury
Molecules · 2023
DOI: 10.3390/molecules28104147 ↗At a glance
Journal article in Molecules, 2023. Written by Xinghua Guo and 6 co-authors. Institution: Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China. Major MEDLINE topics: Chitosan, Glycyrrhetinic Acid, Chemical and Drug Induced Liver Injury, Chronic, Nanoparticles. Cited 7 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: not applicable, The Science and Technology Program of Guangzhou, China, The Guangdong Demonstration Base for Joint Cultivation of Postgraduates.
Abstract (original language)
Objective: the study was to find a suitable treatment for acute drug-induced liver injury. The use of nanocarriers can improve the therapeutic effect of natural drugs by targeting hepatocytes and higher loads. Methods: firstly, uniformly dispersed three-dimensional dendritic mesoporous silica nanospheres (MSNs) were synthesized. Glycyrrhetinic acid (GA) was covalently modified on MSN surfaces through amide bond and then loaded with COSM to form drug-loaded nanoparticles (COSM@MSN-NH2-GA). The constructed drug-loaded nano-delivery system was determined by characterization analysis. Finally, the effect of nano-drug particles on cell viability was evaluated and the cell uptake in vitro was observed. Results: GA was successfully modified to obtain the spherical nano-carrier MSN-NH2-GA (≤200 nm). The neutral surface charge improves its biocompatibility. MSN-NH2-GA has high drug loading (28.36% ± 1.00) because of its suitable specific surface area and pore volume. In vitro cell experiments showed that COSM@MSN-NH2-GA significantly enhanced the uptake of liver cells (LO2) and decreased the AST and ALT indexes. Conclusion: this study demonstrated for the first time that formulation and delivery schemes using natural drug COSM and nanocarrier MSN have a protective effect on APAP-induced hepatocyte injury. This result provides a potential nano-delivery scheme for the targeted therapy of acute drug-induced liver injury.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510310, China.
- Guangzhou Rainhome Pharm & Tech Co., Ltd., Science City, Guangzhou 510663, China.
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China.
ORCID profiles: Zhengquan Su
Funding
- not applicable
- The Science and Technology Program of Guangzhou, China
- The Guangdong Demonstration Base for Joint Cultivation of Postgraduates
- The Science Foundation for Distinguished Young Scholars of Guangdong
Cite
APA
Guo, X., Zhang, C., Bai, Y., Che, Q., Cao, H., Guo, J., & Su, Z. (2023). Synthesis of Chitosan Oligosaccharide-Loaded Glycyrrhetinic Acid Functionalized Mesoporous Silica Nanoparticles and In Vitro Verification of the Treatment of APAP-Induced Liver Injury. Molecules. https://doi.org/10.3390/molecules28104147
Vancouver
Guo X, Zhang C, Bai Y, Che Q, Cao H, Guo J, et al. Synthesis of Chitosan Oligosaccharide-Loaded Glycyrrhetinic Acid Functionalized Mesoporous Silica Nanoparticles and In Vitro Verification of the Treatment of APAP-Induced Liver Injury. Molecules. 2023. doi:10.3390/molecules28104147
BibTeX
@article{Guo2023,
author = {Guo, Xinghua and Zhang, Chengcheng and Bai, Yan and Che, Qishi and Cao, Hua and Guo, Jiao and Su, Zhengquan},
title = {Synthesis of Chitosan Oligosaccharide-Loaded Glycyrrhetinic Acid Functionalized Mesoporous Silica Nanoparticles and In Vitro Verification of the Treatment of APAP-Induced Liver Injury},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28104147}
}
EUVIMED